ArticleThe Journal of biological chemistry2026
Transcriptome-guided discovery and active-site gatekeeper engineering of a Viola arcuata asparaginyl ligase with superior catalytic performance.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide macrocyclization by ligase-type asparaginyl endopeptidases (AEPs) underpins many emerging applications in peptide and protein engineering, yet only a few recombinant ligases currently offer suitable catalytic performance and operational robustness. Here we characterize VaPAL2, a previously unreported AEP from Viola arcuata, and show that its activity can be substantially enhanced through a single gatekeeper substitution. The engineered variant, VaPAL2(I244A), functions as a highly efficient peptide ligase, displaying rapid macrocyclization of GN-type substrates, strong ligation bias on branched sequences, and markedly improved tolerance to organic cosolvents such as 20% DMSO. Notably, VaPAL2(I244A) retains its high activity at near-neutral pH, making it compatible with preparative and protein-compatible conditions. Structural modeling indicates that the I244A substitution modestly widens the S1'-S2 substrate corridor, facilitating nucleophile entry while preserving the catalytic architecture. Together, these findings establish VaPAL2(I244A) as a new, robust macrocyclase that matches or exceeds the performance of widely used recombinant AEP ligase benchmarks under standardized conditions and meaningfully expands the enzymatic toolbox available for chemical biology and peptide engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.